The U.S. unit of Indian drugmaker Dr. Reddy’s Laboratories is recalling 331,590 bottles of cinacalcet tablets used to treat hyperparathyroidism due to the presence of a known carcinogen. | The U.S.

"The addition of Jnana's drug discovery technology and small molecule pipeline in PKU and autoimmune diseases will strengthen our R&D in the Boston area of the US, one of the most important ...

Shares in Synlogic have halved in value after the company reported that a phase 3 trial of its main pipeline drug for rare metabolic disorder phenylketonuria (PKU) failed to show efficacy ...

such as Phenylketonuria (PKU) and Maple Syrup Urine Disease (MSUD). Group 3 covers conditions like Gaucher Disease and Pompe ...

Considering taking supplements to treat phenylketonuria pku? Below is a list of common natural remedies used to treat or reduce the symptoms of phenylketonuria pku. Follow the links to read common ...

This drug is intended for the treatment of phenylketonuria (PKU) in both pediatric and adult patients, covering all age groups and disease subtypes. The company also announced the recent ...

has accepted for filing its New Drug Application (NDA) for sepiapterin, a treatment designed for both pediatric and adult patients with phenylketonuria (PKU). The company expects to receive a ...

NGGT has initiated Phase I/II clinical trials in the U.S. and China to evaluate the safety and efficacy of NGGT002 for the <a ta ...

New Study Results Indicate Superior Absorption of RLF-OD032 in Fasted State Compared to KUVAN®, Potentially Enabling Flexible Dosing Options GENEVA, SWITZERLAND / ACCESSWIRE / October 25, 2024 /RELIEF ...

This drug is intended for the treatment of phenylketonuria (PKU) in both pediatric and adult patients, covering all age groups and disease subtypes. The company also announced the recent publication ...

The patents, based on these new findings, cover additional claims for Relief’s investigational drug RLF-OD032, a highly concentrated, novel liquid formulation of sapropterin dihydrochloride, for the ...